Prior to the agency’s announcement via news release, the intravenous treatment had been limited to hospitalized COVID-19 patients.
Remdesivir reduced hospitalizations in COVID-19 patients at high risk for severe progression of the disease, according to data published in December in the New England Journal of Medicine.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
